IMMUNE MONITORING WITH UREA-FORMULATED EBV PROTEINS FOR PREDICTION OF EBV REACTIVATION IN RENAL TRANSPLANT PATIENTS

被引：0

|

作者：

Barabas, S. ^{[1
,2
]}

Zeman, F. ^{[3
]}

Pfister, A. ^{[2
]}

Bendfeldt, H. ^{[1
]}

Starke, A. ^{[1
]}

Jilg, W. ^{[2
]}

Wolf, H. ^{[2
]}

Koller, M. ^{[3
]}

Banas, B. ^{[4
]}

Kraemer, B. K. ^{[5
]}

Deml, L. ^{[1
,2
]}

机构：

[1] Lophius Biosci GmbH, Regensburg, Germany

[2] Univ Med Ctr, Inst Med Microbiol & Hyg, Regensburg, Germany

[3] Univ Med Ctr, Ctr Clin Studies, Regensburg, Germany

[4] Univ Med Ctr, Dept Internal Med 2, Regensburg, Germany

[5] Univ Heidelberg, Med Fac Mannheim, D-6800 Mannheim, Germany

来源：

TRANSPLANT INTERNATIONAL | 2011年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

引用

收藏

页码：57 / 57

页数：1

相关论文

共 43 条

[41] Epstein-Barr Virus Viral Load Monitoring in High Risk, EBV Donor Seropositive (D plus ), Recipient Seronegative (R-), Adult and Pediatric Solid Organ Transplant (SOT) Patients Decreases Early Posttransplant Lymphoroloferative Disorder (PTLD)
Doucette, Karen
Dicken, Bryan
Bigam, David
Preiksaitis, Jutta
AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 472 - 472
[42] PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques: A safety study
Carroll, R.
Zalcberg, J. R.
Tang, H.
ANNALS OF ONCOLOGY, 2018, 29
[43] Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring
Cicinnati, V. R.
Yu, Z.
Klein, C. G.
Sotiropoulos, G. C.
Saner, F.
Malago, M.
Frilling, A.
Gerken, G.
Broelsch, C. E.
Beckebaum, S.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (09) : 1195 - 1208

← 1 2 3 4 5 →